Cargando…
Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats
Pulmonary arterial hypertension (PAH) is a progressive disease caused by increased pulmonary artery pressure and pulmonary vascular resistance, eventually leading to right heart failure until death. Soluble guanylate cyclase (sGC) has been regarded as an attractive drug target in treating PAH. In th...
Autores principales: | Tong, Yi, Jiao, Qian, Liu, Yuanru, Lv, Jiankun, Wang, Rui, Zhu, Lili |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160570/ https://www.ncbi.nlm.nih.gov/pubmed/30298002 http://dx.doi.org/10.3389/fphar.2018.01032 |
Ejemplares similares
-
Protective Effects of 18β-Glycyrrhetinic Acid on Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats
por: Zhang, Min, et al.
Publicado: (2019) -
Naringin Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension Through Endothelial-To-Mesenchymal Transition Inhibition
por: Wu, Yonghui, et al.
Publicado: (2021) -
Arctigenin prevents monocrotaline-induced pulmonary arterial hypertension in rats
por: Jiang, Wei-Long, et al.
Publicado: (2019) -
Expression profile of matricellular proteins in hypertrophied right ventricle
of monocrotaline-induced pulmonary hypertensive rats
por: IMOTO, Keisuke, et al.
Publicado: (2017) -
Maprotiline Suppresses Cholesterol Biosynthesis and Hepatocellular Carcinoma Progression Through Direct Targeting of CRABP1
por: Zheng, Cancan, et al.
Publicado: (2021)